Page last updated: 2024-09-05

sorafenib and pemetrexed

sorafenib has been researched along with pemetrexed in 12 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(pemetrexed)
Trials
(pemetrexed)
Recent Studies (post-2010) (pemetrexed)
6,5207305,2512,4696571,695

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)pemetrexed (IC50)
Thymidylate synthase Escherichia coli1.1
Dihydrofolate reductaseHomo sapiens (human)4.0309
Dihydrofolate reductaseLacticaseibacillus casei2.3
Thymidylate synthaseHomo sapiens (human)8.1787
Dihydrofolate reductaseEscherichia coli K-122.3
Folate receptor betaHomo sapiens (human)0.2585
Folate receptor alphaHomo sapiens (human)0.2417
Trifunctional purine biosynthetic protein adenosine-3Homo sapiens (human)0.0342
Bifunctional purine biosynthesis protein ATICHomo sapiens (human)0.07
Reduced folate transporterHomo sapiens (human)0.0928
Bifunctional dihydrofolate reductase-thymidylate synthaseToxoplasma gondii1.655
Proton-coupled folate transporterHomo sapiens (human)0.0229

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's11 (91.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Hanna, N1
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM1
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A1
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y1
Allegood, J; Bareford, MD; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Ogretmen, B; Park, MA; Poklepovic, A; Spiegel, S1
Chen, J; Chen, L; Jiang, Y; Li, C; Li, Y; Ma, Y1
Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z1
Boone, DL; Booth, L; Chuckalovcak, J; Dent, P; Koromilas, AE; McGuire, WP; Poklepovic, A; Roberts, JL; Stringer, DK; Tavallai, M1
Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W1
Booth, L; Dent, P; Poklepovic, A; Roberts, JL1

Reviews

1 review(s) available for sorafenib and pemetrexed

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

4 trial(s) available for sorafenib and pemetrexed

ArticleYear
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome

2006
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate

2013
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
    Oncotarget, 2016, 07-05, Volume: 7, Issue:27

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib; Treatment Outcome; Triple Negative Breast Neoplasms

2016

Other Studies

7 other study(ies) available for sorafenib and pemetrexed

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Cancer research, 2011, Jul-15, Volume: 71, Issue:14

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Female; Glutamates; Guanine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution

2011
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
    Autophagy, 2011, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
    Cancer biology & therapy, 2012, Volume: 13, Issue:9

    Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Endosomes; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Glutamates; Guanine; Humans; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein Phosphatase 2; Pyridines; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sorafenib; src-Family Kinases

2012
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Clinical laboratory, 2012, Volume: 58, Issue:5-6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2012
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
    Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
    Oncotarget, 2017, Feb-21, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sorafenib; Xenograft Model Antitumor Assays

2017